코 세척 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the nasal irrigation market size is projected to expand from USD 0.42 billion in 2025 and USD 0.5 billion in 2026 to USD 1.14 billion by 2031, registering a CAGR of 18.17% between 2026 to 2031.

This report is Segmented by Product Type (Neti Pots, and More), Technology (Manual, and More), Solution Type (Isotonic, and More), Indication (Chronic Rhinosinusitis, and More), End User (Homecare, and More), Distribution Channel (Retail Pharmacies/Drugstores, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Nasal Irrigation Market Trends and Insights

Rising Prevalence of Allergic Rhinitis and Chronic Rhinosinusitis Fuels Structural Demand

Allergic rhinitis and chronic rhinosinusitis continue to anchor need for daily or seasonal lavage because patients want relief without systemic side effects. Clinical practice in 2026 reflects growing consensus that high-volume irrigation reduces mucosal edema and supports symptom control, especially in chronic rhinosinusitis after surgery. Meta-analytic evidence shows that budesonide nasal irrigation improves disease-specific patient-reported outcomes while maintaining cortisol levels and intraocular pressure within safe ranges, which supports broader clinician confidence.

Patient knowledge remains uneven, as a 2026 cross-sectional study in China reported high current usage of nasal irrigation among rhinosinusitis patients but limited belief in irrigation as an independent disease control strategy, which highlights an education gap that vendors aim to close. When education is combined with structured follow-up, adherence rises during the first week of a sinusitis episode, although it can taper in week two without ongoing engagement. These patterns sustain demand for both consumables and powered systems as part of seasonal and chronic regimens across the nasal irrigation market.

Home-Based Self-Care Migration Redefines Distribution and Device Design

The nasal irrigation market benefits from a clear migration to home-based care as patients adopt OTC hygiene routines. Adherence support delivered through instructions, video links, and delayed-antibiotic strategies improved week-one compliance in controlled trials, although retention in week two required ongoing feedback loops that digital subscriptions can provide.

Homecare users prize convenience and privacy for a procedure that many initially find unpleasant, which shapes product design toward ergonomic controls and quick-clean components. Retail pharmacists continue to educate on saline mixture, temperature, and pediatric safety, yet online channels expand through automated replenishment and instructional content that address known knowledge deficits documented in recent clinical surveys. Companies adapt packaging and app prompts to sustain weekly routines that align with allergy and infection cycles, which keeps the nasal irrigation market active through both seasonal spikes and chronic daily use.

Improper Water Quality and Device Contamination Risks Trigger Safety Mandates

A 2023 fatality in New Mexico due to Acanthamoeba encephalitis linked to tap-water use in an electronic nasal irrigator heightened risk awareness, which prompted renewed emphasis on water safety for sinus rinsing. CDC guidance updated in 2025 states that users should choose distilled, sterile, or boiled-then-cooled water or apply specific disinfection steps before irrigation. The same organism risk framework extends to Naegleria fowleri, which has a very high case-fatality rate when tap water enters nasal passages and accesses the central nervous system.

Public-health instructions add preparation steps that may reduce short-term adherence among some users, which motivates device makers to include clear instructions and reminders inside packaging and apps. Recalls in related nasal-care products such as cotton swabs in 2025 further underscored the need for stringent manufacturing controls and validated cleaning protocols for components that contact mucosa.

Other drivers and restraints analyzed in the detailed report include:

1. Product Innovation in Powered and Pulsatile Irrigation Systems
2. Expanding Use of Medicated and Antiseptic Irrigation
3. Tolerability Issues Limit Adherence Despite Clinical Efficacy

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Squeeze bottles captured a 20.16% share in 2025, reflecting affordability, wide retail availability, and clinician familiarity in starter kits. Buyers value simple ergonomics and universal compatibility with premixed saline packets or home-mixed isotonic blends, which keeps entry barriers low for new users across the nasal irrigation market. Self-prepared isotonic solutions remain common for everyday hygiene, and premixed sachets reduce mixing errors in households that want predictable pH and tonicity. Manual bottle design has focused on grip, valve reliability, and one-handed operation to reduce learning curves for first-time users who may be apprehensive about discomfort. Specialty products like compressor-assisted nasal showers occupy a niche in European pharmacies where durable medical equipment is popular with ENT prescribers and outpatient clinics.

Electric and pulsatile systems are forecast to grow at a 21.19% CAGR through 2031 as they segment the user base with more personalization, pressure control, and integrated hygiene features. Flagship models advertise pulsation at 1,200 cycles per minute, variable speeds, and rinse-plus-suction flows designed to limit cross-pass contamination and reduce perceived effort. Designs now incorporate antimicrobial housings and self-clean cycles to reinforce confidence around contamination and cleaning routines, which addresses a central restraint. Safety innovation includes pressure-release valves that cap output to levels set to minimize epistaxis and barotrauma risk, answering one of the most cited tolerability concerns. Cordless, foldable, and IPX-rated devices expand usage into travel and work settings, which increases monthly active use days and supports replenishment cadence for saline packets.

Manual technology held a 65.23% share in 2025, reflecting low device cost, near-universal saline compatibility, and broad placement across retail pharmacies and physician offices. Manual systems remain popular in early adoption because the learning curve is short, the price point is low, and results are visible, particularly during peak allergy seasons. As clinicians coach on temperature and head position, many users resolve early discomfort and continue use through pollen surges and cold seasons. Bottles increasingly feature removable, dishwasher-safe parts, which reduces routine cleaning barriers that can lead to drop-off in week two of new use.

Electric and battery-powered systems are projected to expand at a 20.15% CAGR through 2031, driven by lithium-polymer batteries, USB-C common charging, and microprocessor-controlled pressure profiles. Modern devices advertise multiple intensity levels for varied anatomy and sensitivity, alongside attached reservoirs that balance volume with portability. Rinse-and-suction functionality provides a differentiated experience that reduces time per session for busy users who still want thorough clearance. Pressure caps as low as 7 kPa aim to protect the middle ear and fragile mucosa, which underscores a safety-first approach in the emerging premium tier of the nasal irrigation industry. As these capabilities filter into mid-tier prices, the nasal irrigation market will see continued mix-shift toward electric platforms in both developed and fast-growing regions.

Geography Analysis

North America held a 38.17% share in 2025, underpinned by a large burden of allergic disease and widespread clinician and pharmacist engagement with irrigation across acute and chronic use. Routine post-FESS irrigation protocols are entrenched in specialty care, which sustains device and consumables demand across hospitals, clinics, and home transitions. The region supports higher adoption of powered devices relative to other geographies due to disposable income and access to clinical coaching, which favors premium features like pulsation and self-clean cycles. Water-safety guidance is prominent and now common in device leaflets and web pages, which shapes behavior and maintains focus on sterile or boiled-then-cooled water.

Asia-Pacific is projected to expand at a 20.14% CAGR through 2031 as urbanization and air-quality factors increase symptom burdens that point users to daily hygiene routines. As middle-class purchasing power rises, mid-tier powered irrigators assembled locally increase accessibility without sacrificing pressure controls or antimicrobial features. Pharmacy and online channels are both active in educating first-time users with how-to content and refill subscriptions, which supports habitual use after initial trials. Cultural hygiene practices in select markets create a receptive base for device adoption, and clinical training in ENT centers spreads best practices into community settings in the nasal irrigation market.

Europe maintains steady growth as ENT societies and hospital protocols standardize high-volume irrigation after surgery and in chronic care. Compressor-assisted nasal showers hold niche positions in parts of Western Europe through established pharmacy channels that favor durable equipment, while home-based squeeze bottles and emerging electric devices broaden consumer choice. Clinical literature in 2024 and 2025 supports solution selection by balancing efficacy and tolerability, which guides patient counseling and sustains adherence for the nasal irrigation market.

1. Church & Dwight
2. ENT Technologies Pty Ltd
3. Flaem Nuova S.p.A.
4. Health Solutions Medical Products Corp. (SinuPulse)
5. Himalayan Chandra
6. hydraSense
7. Medisana GmbH
8. NeilMed Pharmaceuticals, Inc.
9. RhinoSystems, Inc. (Navage)
10. SQuiP Inc.
11. The Alkalol Company
12. Waterpulse
13. Xlear, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising prevalence of allergic rhinitis and chronic rhinosinusitis
  • 4.2.2 Shift to home-based self-care and OTC nasal hygiene
  • 4.2.3 Product innovation in powered and pulsatile irrigation systems
  • 4.2.4 Expanding use of medicated and antiseptic irrigation (e.g., PVP-iodine, HOCl, xylitol)
  • 4.2.5 ENT postoperative protocols standardizing high-volume irrigation
  • 4.2.6 Guideline endorsements and antibiotic stewardship elevating saline nasal irrigation as first-line adjunct in rhinosinusitis
• 4.3 Market Restraints
  • 4.3.1 Improper water quality and device contamination risks
  • 4.3.2 Tolerability issues (irritation, epistaxis) limiting adherence
  • 4.3.3 Availability of alternative intranasal therapies (steroids, antihistamines, decongestants)
  • 4.3.4 Cleaning/maintenance burden reducing long-term adherence
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Neti Pots
  • 5.1.2 Squeeze Bottles (positive-pressure LVLP)
  • 5.1.3 Syringes/Bulb Syringes
  • 5.1.4 Powered/Pulsatile/Electric Systems
  • 5.1.5 Nasal Douches/Showers (compressor-assisted)
• 5.2 By Technology
  • 5.2.1 Manual
  • 5.2.2 Electric/Battery-Powered
• 5.3 By Solution Type
  • 5.3.1 Isotonic Saline
  • 5.3.2 Hypertonic Saline
  • 5.3.3 Additive-enhanced (e.g., xylitol, povidone-iodine, HOCl, corticosteroid admixture per Rx)
• 5.4 By Indication
  • 5.4.1 Chronic Rhinosinusitis (with/without polyps)
  • 5.4.2 Allergic Rhinitis
  • 5.4.3 Upper Respiratory Infection/Cold & Flu
  • 5.4.4 Post-operative ENT Care (post-FESS/septoplasty)
• 5.5 By End User
  • 5.5.1 Homecare
  • 5.5.2 Hospitals
  • 5.5.3 ENT/Allergy Clinics
• 5.6 By Distribution Channel
  • 5.6.1 Retail Pharmacies/Drugstores
  • 5.6.2 E-commerce/Direct-to-Consumer
  • 5.6.3 Hospital/Clinic Pharmacies & B2B
• 5.7 By Geography
  • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
  • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
  • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
    • 5.7.3.4 Australia
    • 5.7.3.5 South Korea
    • 5.7.3.6 Rest of Asia-Pacific
  • 5.7.4 Middle East and Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East and Africa
  • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 Church & Dwight Co., Inc.
  • 6.3.2 ENT Technologies Pty Ltd
  • 6.3.3 Flaem Nuova S.p.A.
  • 6.3.4 Health Solutions Medical Products Corp. (SinuPulse)
  • 6.3.5 Himalayan Chandra
  • 6.3.6 hydraSense
  • 6.3.7 Medisana GmbH
  • 6.3.8 NeilMed Pharmaceuticals, Inc.
  • 6.3.9 RhinoSystems, Inc. (Navage)
  • 6.3.10 SQuiP Inc.
  • 6.3.11 The Alkalol Company
  • 6.3.12 Waterpulse
  • 6.3.13 Xlear, Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment